Stool-based screening for colorectal cancer may be sharper in women than in men, and the reason traces back to sex-specific differences in gut bacteria. A screening-cohort analysis of microbiome signatures found that microbial shifts tied to colorectal lesion development were more pronounced in female participants. The finding raises a pointed question for the roughly 150,000 Americans diagnosed with colorectal cancer each year: should the thresholds used in stool tests be calibrated differently for women and men?
Why sex-specific microbiome signals matter for colon cancer screening
Most stool-based cancer tests treat all patients the same, regardless of sex. But accumulating evidence suggests that the bacterial communities living in a healthy woman’s gut look different from those in a healthy man’s gut, and that those differences change how clearly a tumor-related signal stands out. A population-based screening cohort study reported that microbiome signatures of colorectal lesion development were stronger in women than in men, even at early disease stages.
The biological logic is straightforward. Premenopausal women carry higher gut microbiota diversity and higher levels of beneficial taxa than men of the same age, according to research published in Nature Aging. That richer baseline creates a steeper drop when cancer-associated bacteria begin to take over. In practical terms, a single stool sample from a woman may capture a larger contrast between “healthy” and “abnormal” than the same snapshot from a man, where baseline diversity is lower and the shift is subtler.
A peer-reviewed study evaluating sex-dependent trajectories during colorectal cancer development found that alpha diversity, a standard measure of bacterial richness, decreased significantly in females as disease progressed. In males, the same measure showed no significant change. That asymmetry means a one-size-fits-all diagnostic cutoff could miss early signals in men while catching them in women.
Large datasets confirm reproducible but sex-uneven microbial markers
The sex gap does not appear in a single small study. It shows up across some of the largest microbiome datasets assembled to date. A pooled analysis of 3,741 stool metagenomes from 18 cohorts identified reproducible microbial biomarkers across cancer stages, including strain-level signals from Fusobacterium-related clades; this large metagenomic study confirmed that certain bacterial markers hold up across geographies and study designs. Yet when researchers have stratified results by sex, the signals separate unevenly, with women often showing clearer case–control contrasts.
A colonoscopy-anchored cohort using shotgun metagenomics enrolled 1,762 participants, roughly half of them female, and tracked microbiome signatures across lesion stages from no neoplasia through advanced lesions and cancer. Published in Gut, the study offered a detailed map of when stool microbial signatures become detectable as disease advances and highlighted that several taxa associated with neoplasia shifted more sharply in women.
Separately, a 616-participant cohort pairing fecal metagenomics with metabolomics defined stage-specific phenotypes of the gut microbiota in colorectal cancer, reinforcing the idea that microbial and metabolic changes track with tumor progression. In that analysis, metabolites linked to microbial fermentation and bile acid metabolism shifted alongside bacterial composition, again with hints that female participants showed more pronounced gradients between healthy tissue, adenomas, and carcinomas.
Tissue-level evidence adds another layer. A study using droplet digital PCR and 16S sequencing in a population-based registry subset found that female sex was associated with both the presence and enrichment of Fusobacterium nucleatum in colorectal tumor tissue. F. nucleatum is one of the most consistently identified bacterial players in colorectal cancer, and its stronger association with female tumors suggests the sex difference is not limited to stool samples but extends into the tumor microenvironment itself.
Mechanistic reviews point to sex hormones as a likely driver. Estrogen and androgens influence both immune regulation and microbial community composition. A peer-reviewed synthesis of sex differences in colorectal cancer highlighted how estrogen-mediated immune modulation and hormone-driven shifts in gut flora could explain why women’s microbiomes respond differently to tumor development. These hormonal effects may also help explain why the diversity gap between women and men narrows after menopause, potentially reducing the diagnostic advantage in older female patients.
Gaps that stand between lab findings and better screening
No published study yet provides sex-specific odds ratios or area-under-the-curve values for microbiome-based classifiers within the same screening cohort. Researchers can say the signal is stronger in women, but they cannot yet quantify how much more accurate a sex-adjusted stool test would be. Without those numbers, clinical guidelines have no basis for recommending different thresholds or separate interpretive charts for women and men.
Longitudinal stool samples collected before a cancer diagnosis and stratified by both sex and menopausal status are also missing from the available datasets. Cross-sectional studies capture a snapshot, but they cannot confirm whether the female-specific diversity drop precedes tumor formation or simply accompanies it. Pre-diagnostic samples would clarify whether microbial shifts in women emerge years before visible lesions, which would strengthen the case for lowering test thresholds for female patients in their 40s and 50s.
Another missing piece is direct comparison between microbiome-based stool tests and existing fecal immunochemical tests (FIT) when both are optimized separately for women and men. Current head-to-head evaluations typically apply identical cutoffs across sexes. If male microbiome signals are inherently weaker, equal thresholds will systematically favor sensitivity in women and sacrifice performance in men. Rigorous trial designs would need to test sex-tailored cutoffs against standard uniform cutoffs to determine whether any gain in sensitivity or specificity justifies added complexity.
Statistical modeling also remains underdeveloped. Many published classifiers treat sex as a simple covariate or adjust for it as a confounder, rather than allowing sex-specific models or interaction terms to shape how individual taxa contribute to risk scores. A more nuanced approach would let the same bacterial species carry different weights in male and female models, reflecting the underlying biology instead of averaging it away.
What sex-aware stool tests might look like
Translating these findings into practice would not necessarily require new collection kits or lab workflows. Instead, sex-aware screening could be implemented at the analytics and reporting stages. Laboratories could apply sex-specific algorithms to the same raw sequencing data, generating separate risk scores for women and men. Reports might include sex-adjusted reference ranges, much like how some blood tests already provide different normal values by sex.
In parallel, developers of next-generation stool tests could design validation trials that pre-specify sex-stratified endpoints. Rather than reporting a single overall sensitivity and specificity, they would publish performance metrics for women and men separately, along with calibration curves showing how predicted risk aligns with observed outcomes in each group. Regulators and guideline committees could then judge whether sex-specific thresholds meaningfully improve detection without creating confusion for clinicians and patients.
For now, the take-home message is less about changing how individual patients are screened and more about how future tools are developed. The emerging microbiome data argue that women and men do not present the same microbial backdrop when colorectal tumors begin to form. Ignoring that difference risks building “average” tests that work best for the group whose signal is loudest. Accounting for sex in study design, modeling, and validation is a straightforward step toward more equitable and effective stool-based screening.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
